Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
15.33
-0.39 (-2.48%)
Jul 24, 2026, 4:00 PM EDT - Market closed

Janux Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
9358333,162496548814
Market Cap Growth
-40.29%-73.65%537.19%-9.45%-32.65%-
Enterprise Value
0.08-111.122,160176.8246.38438.96
Last Close Price
15.3313.8053.5410.7313.1719.73
PS Ratio
68.0883.33298.6761.4063.64223.74
PB Ratio
0.990.873.091.441.712.22
P/TBV Ratio
1.010.892.811.371.701.27
EV/Sales Ratio
0.01-11.11204.0221.8728.61120.69
EV/EBITDA Ratio
-0.71----
EV/EBIT Ratio
-0.70----
EV/FCF Ratio
-1.33----
Debt / Equity Ratio
0.020.020.020.070.080
Net Debt / Equity Ratio
-0.99-0.99-0.98-0.93-0.94-1.02
Net Debt / EBITDA Ratio
6.036.0710.354.504.5511.42
Net Debt / FCF Ratio
11.9111.3422.696.096.1120.30
Asset Turnover
0.010.010.010.020.020.02
Quick Ratio
16.8338.6758.7226.4019.8129.30
Current Ratio
17.0139.0459.2126.8020.1429.46
Return on Equity (ROE)
-12.06%-11.48%-10.09%-17.53%-18.36%-17.50%
Return on Assets (ROA)
-15.47%-15.28%-13.71%-19.61%-18.04%-16.63%
Return on Invested Capital (ROIC)
-553.55%-546.79%-317.42%-224.49%-379.76%-801.00%
Return on Capital Employed (ROCE)
-16.13%-15.61%-14.01%-20.42%-18.78%-17.33%
Buyback Yield / Dilution
-9.22%-15.28%-22.12%-6.14%-76.24%-2471.20%
Total Shareholder Return
-9.22%-15.28%-22.12%-6.14%-76.24%-2471.20%
SEC Filings: 10-K · 10-Q